Back to search
Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Mixed Neuroendocrine-Non Neuroendocrine Neoplasm trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Mixed Neuroendocrine-Non Neuroendocrine Neoplasm trials you may qualify forThis phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come ba…
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with…
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients…
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II,…
For GEP mixed neuroendocrine (NE) non-neuroendocrine neoplasms (MiNENs) a key issue affecting prognosis is sometimes the difficulty in obtaining a timely diagno…
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the…
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipil…